Buchumschlag

An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs

Weitere Versionen anzeigen (1)

Aim: An ultrasensitive UPLC-MS/MS assay for liraglutide was developed and validated according to US FDA and EMA guidelines and applied to the quantification of plasma concentrations after intravenous, nasal and oral administration of liraglutide to beagle dogs. Results: Liraglutide isolation was per...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sauter, Max (VerfasserIn) , Uhl, Philipp (VerfasserIn) , Majewsky, Marius (VerfasserIn) , Fresnais, Margaux (VerfasserIn) , Haefeli, Walter E. (VerfasserIn) , Burhenne, Jürgen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 16 May 2019
In: Bioanalysis
Year: 2019, Jahrgang: 11, Heft: 9, Pages: 887-898
ISSN:1757-6199
DOI:10.4155/bio-2018-0322
Online-Zugang:Verlag, Volltext: https://doi.org/10.4155/bio-2018-0322
Verlag, Volltext: https://www.future-science.com/doi/10.4155/bio-2018-0322
Volltext
Verfasserangaben:Max Sauter, Philipp Uhl, Marius Majewsky, Margaux Fresnais, Walter E Haefeli and Jürgen Burhenne
Beschreibung
Zusammenfassung:Aim: An ultrasensitive UPLC-MS/MS assay for liraglutide was developed and validated according to US FDA and EMA guidelines and applied to the quantification of plasma concentrations after intravenous, nasal and oral administration of liraglutide to beagle dogs. Results: Liraglutide isolation was performed with a combined protein precipitation and solid-phase extraction protocol. The calibrated concentration range of 0.1-200 ng/ml was linear with correlation coefficients >0.998. Precise analysis was achieved through the utilization of an isotopically labeled internal standard. Absolute bioavailability of liraglutide after nasal and oral administration of liraglutide to beagle dogs was 0.03 and 0.006%, respectively. Conclusion: The assay matches the performance in sensitivity of the previously applied immunoassay and optimally covers the therapeutic range of liraglutide.
Beschreibung:Gesehen am 25.10.2019
Beschreibung:Online Resource
ISSN:1757-6199
DOI:10.4155/bio-2018-0322

Ähnliche Einträge